Rx-360 Establishes Asia Working Group - India

USA - English

• India - English

WASHINGTON, May 12, 2015 /PRNewswire-USNewswire/ -- Rx-360, an international, non-profit supply chain consortium, announced today, the formation of the Rx-360 Asia Working Group – India. The Working Group will be led by Anish Swadi, Vice President, Business Development at Hikal, Huzefa Hussain, Manager-Quality Assurance at Amgen, and Prashant Wani, Senior Supplier Auditor at Eli Lilly & Company. The Working Group held an initial face to face meeting in Mumbai, India on February 24, 2015.   Meeting attendees were from global and local India pharmaceutical and supplier companies. 

The Rx-360 Working Group - Asia has had a vibrant group in Shanghai for almost 2 years.   Given the size of India's pharma market and its importance as a manufacturer and exporter of APIs and drug product to North America and Europe, Rx-360 believed it was important to also develop a presence in India.   

The Working Group will focus its attention on identifying and mitigating root causes of quality problems and supply chain security.  As a neutral, open, and consensus building industry forum, Rx-360 seeks to help address these quality challenges and support India industry.

The Working Group's goals are to:

• Build Rx-360's reputation and credibility in India as a group with tools to solve problems relevant to the global pharma industry and supply chain;
• Help understand and mitigate root causes of the most pressing quality challenges;
• Share best practices and case studies from sites;
• Spread awareness and understanding about Rx-360, its activities, and its audit programs, in India among India-based suppliers and manufacturers; and
• Position Rx -360 as a mentoring resource for the India pharma industry.

The Rx-360 India Working Group has prepared a survey to solicit feedback from individuals who may have encountered data integrity (DI) issues in the course of their work in GMP sites located in India. The purpose of this survey is to benchmark experiences and mitigation strategies. The survey is voluntary, confidential and anonymous. Results of the survey will be shared individually with participating companies.  The intent of the survey is to gather benchmarking information to develop educational materials and other efforts that can help to advance data integrity understanding and mitigations.

To access the survey, please click here: Rx-360 India WG Data Integrity Survey.

The Working Group will be scheduling a public webinar shortly which will include an overview of Rx-360, an introduction to Rx-360 Asia WG – India, and introduction to the Rx-360 audit programs.   An announcement will be circulated shortly.  Please visit the Rx-360 website (www.rx-360.org) to sign up for Flash Alerts to receive information about the upcoming webinar.

Rx-360, an international pharmaceutical supply chain consortium, was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain.  The organization's mission is to protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain. To fulfill this mission, Rx-360 has workstreams related to: conduction and sharing of audits, supply chain security, monitoring and reporting, Asia-focused efforts, supplier-focused efforts, and external relations, communications, and membership. To learn more about Rx-360, please visit www.Rx-360.org or email [email protected].

SOURCE Rx-360